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Background: Previous reports assessing the neuroprotective role of nonselective Nitric Oxide synthase (NOS)
inhibitor N-nitro-L-arginine-methylester (L-NAME) following cerebral ischemia/reperfusion are contradictory. The aim
of this work was to examine the potential benefits of L-NAME on rats subjected to transient focal cerebral ischemia/
reperfusion.
Methods: The study involved 30 adult male Wistar rats divided into three groups 10 rats in each: First group was
sham-operated and served as a control, a ischemia/reperfusion (I/R) group of rats infused with 0.9% normal saline
intraperitoneally 15 minutes prior to 30 minutes of left common carotid artery (CCA) occlusion and a test group
infused with L-NAME intraperitoneally 15 minutes prior to ischemia. Neurobehavioral assessments were evaluated
and quantitative assessment of malondialdehyde (MDA), Nitric oxide (NO) metabolites and total antioxidant
capacity (TAC) in both serum and the affected cerebral hemisphere were achieved.
Results: Rats’ neurological deficit and TAC were significantly decreased while NO and MDA were significantly increased
in the I/R compared with the control group (P < 0.001). Alternatively in the L-NAME group, neurological deficit and TAC
were significantly improved while NO and MDA were significantly decreased compared to I/R group (P < 0.001).
Conclusions: L-NAME pretreatment for rats undergoing cerebral ischemia/reperfusion significantly improves
neurological deficit while reducing oxidative stress biomarkers in the affected cerebral hemisphere.
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NO is synthesized from its precursor L-arginine by the
action of NOS and proved to be a vital cellular signaling
molecule in the central nervous system [1]. Three NOS
isoforms have been identified in the brain following the
onset of cerebral ischemia [2]; however, their exact
pathophysiological role in cerebral ischemia/reperfusion
is uncertain [3,4]. NO produced by endothelial NOS
(eNOS) was proved to be beneficial during cerebral
ischemia/reperfusion. This is because of its vasodilator
and antiplatelet effects [5]. In addition, NO increases
vascular smooth muscle proliferation and migration, so
enhances angiogenesis after stroke [6]. In contrast, the* Correspondence: h_alsheekh82@yahoo.com
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reproduction in any medium, provided the orneuronal and inducible isoforms of NOS (nNOS, iNOS)
can be neurotoxic [7], probably because they enhance
peroxynitrite production, a free radical involved in lipid
peroxidation, suppress mitochondrial respiratory enzymes
and damage DNA. NO can directly inhibit enzymes
needed for mitochondrial respiration, glycolysis and DNA
replication [8]. Accordingly, inhibition of NOS and hence
decreasing NO production may be valuable while treating
patients with acute stroke. However, previous studies
evaluating the possible effects of nonselective NOS inhibi-
tor L-NAME in the experimental stroke model are
contradictory. The results ranged from reduction [9] to
no effect [10] or even a worsening of ischemic neuronal
damage [11,12]. This study aimed to explore the potential
anti-oxidant effect of L-NAME in rats with transient focal
cerebral ischemia/reperfusion.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Animals
The animals were handled in accordance with the ethical stan-
dards laid down in the US National Institutes of Health (NIH
Publication No. 85–23) and its later revisions. Male Wis-
tar rats, weighing 150–250 g were selected and pre-
served at a constant temperature of 22±2°C with a
fixed 12:12-h light–dark cycle. Nutritionally balanced
pellets and water were freely available.
Experimental design
Three randomly divided experimental groups were used,
of 10 rats each: (1) sham operated: which included full
surgical preparation without common carotid artery
(CCA) occlusion serve as control group (2) ischemia/
reperfusion (I/R) group: Brain ischemia was maintained
for 30 minutes of left CCA occlusion followed by
24 hours reperfusion. All rats in this group received
0.9% normal saline intraperitoneally 15 minutes prior to
induction of ischemia [11]. The volume of saline infused
was equivalent to the volume of L-NAME received by
the third group.
(3) L-NAME (Sigma aldrich Co., Ltd.) 15 mg/kg over
5 minutes intraperitoneally (i.p) 15 minutes before left
CCA occlusion [11].
Cerebral ischemia induction
The animals were fasted overnight prior to surgery with
free access to tap water. Anesthesia was induced by
ether inhalation and maintained by thiopental sodium
(2.5 mg/kg) [13]. Body temperature was kept constant at
36.5±0.5°C using heating pad. A longitudinal cervical
incision (2 cm) was made lateral to the midline and the
CCA was carefully dissected. Ischemia was induced by
placing non traumatic microvascular clip on left CCA
just prior to its bifurcation [14]. During ischemia rats
were monitored for body temperature and respiration
pattern. The vascular occlusion was maintained for
30 minutes, and then the clips were removed to resume
blood flow to the ischemic region for 24 hours [11].
Finally, the incisions were sutured, the animal was allowed
to recover from anesthesia, and returned to a warm cage
for recuperation during reperfusion period.
Neurological and behavioral evaluation
Neurobehavioral tests of all experimental groups were
assessed daily to determine the effect of ischemic injury
on them. Neurobehavioral evaluations were performed
three times: the day before surgery, the same day as
surgery and just before killing the animals. Each rat was
examined in the late afternoon hours so that rats that
had been operated in the morning would fully recovered
from the effects of anesthesia by the time of evaluation.
The neurobehavioral study consisted of the following sixtests: spontaneous activity, symmetry in the movement
of the four limbs, forepaw outstretching, climbing, body
proprioception and response to vibrissae touch. The
score given to each rat at the end of the evaluation is the
summation of all six individual test scores. The minimum
neurological score was 3 and the maximum was 18 [15].
Laboratory investigations
At the end of experimental period, the rats were sacrificed
by decapitation. Brains were rapidly removed from the skull
and washed with cold saline and stored at −20°C for further
analysis. A small part of each brain from the affected
hemisphere was dissected to approximately 1–2 mm
pieces and they were homogenized in 7 ml of ice-cold
extraction buffer (1% Triton X-100, 10 mmol/l MgSO4,
1 mmol/l EDTA, 1 mmol/l dithiothreitol, 0.5 mol/l
NaCl,1% protease inhibitor cocktail, 20 mmol/l HEPES
and pH of 7.5) [16]. The homogenate was centrifuged;
the supernatant was taken and stored at −20°C until being
used. A modification of the method of Lowry was used for
the determination of protein in the brain homogenate [17].
The level of the NO metabolites (nitrite and nitrate) [18,19]
and total antioxidant capacity (TAC) were measured
colorimetrically. Satoh method was used to measure
serum and brain homogenate malondialdehyde (MDA)
levels (an indicator of lipid peroxidation) [20].
Data analysis
Statistical evaluation was performed using the Microsoft
Office Excel (Microsoft Office Excel for windows; 2003)
and SPSS (SPSS for windows version 19). Screening
studied rats’ groups for significant difference in the mean
of MDA, NO and TAC was performed using analysis of
variance. P < 0.05 was considered significant.
Results
As shown in Figure 1, the means of the neurological scores
of both I/R (12.798±0.689) and L-NAME (15.07±0.584)
were significantly lower compared to the control group
(17.50±0.707, P < 0.001). The L-NAME group showed a
significant improvement in neurological deficit compared
to the I/R group (P < 0.001). In addition, I/R group
demonstrated a significant increase in the serum levels of
both MDA and NO (14.88±1.14 nmol/mL, 42.03±4.558
μmol/L respectively) compared to the control group
(5.43±0.44 nmol/mL, 17.84±0.701 μmol/L respectively,
P < 0.001). Alternatively, the L-NAME group showed
significant decrease in serum level of MDA and NO
(7.18±0.135, 18.44±0.513 μmol/L respectively, P < 0.001)
compared to the I/R group (Figure 2). The serum level of
TAC in the I/R group (1.21±0.169 mM/L) was significantly
lower compared to the control group (2.52±0.062 mM/L,
P < 0.001) but not L-NAME group (2.53±0.067 mM/L,
P = 0.858) (Figure 2). L-NAME pretreatment resulted
##
Figure 1 Neurological deficit of sham operated and in ischemia/reperfusion rats with and without L-NAME. * Significant with controls,
Δ Significant with ischemia reperfusion, # Significant with L-NAME.
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rats treated with normal saline (P < 0.001).
Regarding brain tissue levels of MDA and NO, the I/R
group demonstrated a significant increase in the tissue level
of both MDA and NO (8.56±0.658, 8.88±0.572 nmol/mg#
#
Figure 2 Serum level of MDA, NO and TAC in sham operated and in i
with controls, Δ Significant with ischemia reperfusion, # Significant with L-Nprotein) compared to the control group (3.24±0.226,
3.48±0.228 nmol/mg protein, P < 0.001). The L-NAME
group showed a significant decrease in tissue level of
MDA and NO (3.18±0.155, 4.47±0.392 nmol/mg protein,
P < 0.001) compared to the I/R group. The brain TAC#
#
schemia reperfusion rats with and without L-NAME. * Significant
AME.
Awooda et al. Experimental & Translational Stroke Medicine 2013, 5:1 Page 4 of 6
http://www.etsmjournal.com/content/5/1/1level of the I/R group (0.0186±0.00373 mmol/mg protein)
was significantly decreased compared to the control group
(0.070±0.0085 mmol/mg protein, P < 0.001) but not the L-
NAME group (0.0747±0.00563 mmol/mg protein, P = 0.112).
On the contrary, administration of L-NAME prior to is-
chemia result in significant increase of brain TAC level
compare to rats subjected to saline infusion (P < 0.001)
(Figure 3).
Discussion
It is evident from the current findings that oxidative
stress and inflammation are predictable outcome following
cerebral ischemia/reperfusion. The biomarkers of the
offending pathological mechanisms involved in oxidative
stress and neuroinflammation were significantly lowered
by L-NAME administration prior to cerebral ischemia/
reperfusion. This fact suggested a probable anti-oxidant
effect of L-NAME which was evident by the improvement
of the neurological score of rats treated by this medication
prior to cerebral ischemia/reperfusion.
Previous studies carried out to evaluate the effect of
L-NAME in rats subjected to focal or global cerebral
ischemia showed no agreement [21,22], probably due
to the differences between study protocols in terms of
animal species, physiological parameters measured,
surgical approach, duration of ischemia and dosing
regimen [9,22].
Considerable researches were done to determine the
best dosing and timing regimen of L-NAME in terms of#
#
Figure 3 Brain tissue level of MDA, NO and TAC in sham operated an
* Significant with controls, Δ Significant with ischemia reperfusion, # Significneuroprotection [22-24]. Based on previous reports, the
current study used probably the best dosing and timing
regimen of L-NAME. The role of NO in cerebral ischemia
was examined 24 hours after CCA occlusion using a dose
of 15 mg/kg L-NAME, 15 minutes prior to induction of
cerebral ischemia. Ding-Zhou et al. and others, tried
different doses of L-NAME and they found that low doses
(1, 3 and 10 mg/kg) reduced the infarct volume, whereas
a high dose (30 mg/kg) killed 80% of the studied animals.
[9,25,26]. On other hand, Batteur-Parmentier et al. pro-
posed that eNOS contribution to the early NO production
after ischemia may have a beneficial effect by increasing
cerebral blood flow, decreasing platelet aggregation and
neutrophils adhesion [23]. However, L-NAME given during
the acute phase of transient ischemia might fail to reduce
ischemic infarct and even aggravated the ischemic outcome
in models of cerebral ischemia [25,26].
The results of the current study are further supported by
the systematic review conducted by Willmot and his group
[27] which analyzed 2321 models of cerebral ischemia and
proved the beneficial effects of NOS inhibitors including
L-NAME. These beneficial effects include the reduction of
the cerebral lesion size and improved neurological deficit
due to reduced formation of peroxynitrite and reactive
oxygen species (ROS) [28] inhibition of brain edema,
reduced vascular damage, inhibition of apoptosis and
necrosis [9]. It is worth mentioning that inhibition of
NO production induces vasoconstriction and subse-
quently increases blood pressure. However, Ashwal et al.# #
d in ischemia reperfusion rats with and without L-NAME.
ant with L-NAME.
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tive outcome without influencing the blood pressure [29].
These suggestions were compatible with Mohammadi et al.
report that neuroprotective potential of a low dose of
L-NAME as indicated by improving the neurological
deficit, reducing cerebral edema and the infarction volume,
decreased cerebral vascular permeability, with no significant
change in the value of mean arterial blood pressures or
regional cerebral blood flow [12].
Other researches with comparable findings to the
current study regarding the antioxidant effect of L-NAME
on oxidative stress biomarkers include Seif-el-Nasr [30]
and Sayan et al. [31]. Seif-el-Nasr assessed the antioxidant
effect L-NAME in a model of global cerebral ischemia
induced by 60 min of bilateral ligation of the CCA followed
by 60 min of reperfusion period [30]. L-NAME (1 and
3 mg/kg, twice after ischemia and 15 min before termin-
ation of the experiment) produced a significant decrease in
level of lipid peroxidation in the rats’ brains. Sayan et al.
proposed that L-NAME significantly reduced MDA in rat’s
model of sciatic nerve ischemia/reperfusion [31]. In
contrast, Adaramoye et al. reported that as consequence
of L-NAME treatment (40 mg/kg 5 times in a week for
a period of 3 weeks), various oxidative stress parameters
in the blood, kidney, liver and heart were enhanced
[32]. Similarly, L-NAME provoked oxidative stress in
rat’s model of hind legs ischemia/reperfusion [33].
In conclusion, the current study demonstrates the
potential anti-oxidant effect of L-NAME in rat’s focal
cerebral ischemia/reperfusion, through inhibition of
oxidative stress and lipid peroxidation as well as
improvement of neurological deficits.
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